Advanced searches left 3/3

Cefepime - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

Vancomycin With Concomitant Piperacillin/Tazobactam vs. Cefepime or Meropenem Associated Acute Kidney Injury in General Ward Patients: A Multicenter Propensity Score-Matched Study.

Background: Continuous administration of vancomycin and piperacillin/tazobactam in hospitalized patients can raise the risk of acute kidney disease. Objective: To compare the prevalence of AKI related to VAN+PTZ among adult general ward patients with either cefepime or meropenem with VAN. AKI incidences in both study groups was determined by the primary endpoint. According to their respective statistics, AKI in the VAN+PTZ and VAN+CEF/MER groups was 16. 4% and 8. 7%. Compared to VAN+PTZ/MER, the onset of AKI was 1. 8 days earlier. According to a contributing risk factor of AKI, concomitant VAN+PTZ was identified as an independent risk factor of acquiring AKI. Compared to the VAN+CEF/MER group, the VAN+PTZ group had notably higher rates of acute AKI. There were no differences between study groups in the AKI recovery behavior. Conclusions: Concomitant VAN+PTZ in adult general ward patients was not independently associated with an elevated risk of AKI overall.

Source link: https://europepmc.org/article/MED/36075000


Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers.

Both healthcare professionals and patients often question the efficacy and quality of generic antibacterial drug formulations. By comparing bioequival characteristics and stability data of generic cefepime, linezolid, and piperacillin/tazobactam with their respective originator drugs, the present research investigated generic drug interchangeability with their originators. Methods In this open-label, randomized, cross bioequival trial, three groups of 12 healthy volunteers each received a single intravenous infusion of either 2 g of cefepime or 4. 5 g of piperacillin/tazobactam and two generic formulations, or 600 mg of linezolid and one generic formulation. Stability was tested by storing reconstituted generic and originator products according to their own storage requirements and those of the comparator products.

Source link: https://europepmc.org/article/MED/36039038


Cefepime-induced neurotoxicity: systematic review.

In the systematic review, we included 92 papers, including 23 observational studies and 69 cases from case reports and case series. Nearly 90% of the cases had CIN at the time of diagnosis, and nearly all of them had CINs at the time of diagnosis, and nearly half of them had renal dysfunction. Following empirical therapy, the median latency period of CIN derivation from cefepime initiation was 4 days, with around 12% developing CIN. Patients in CIN regularly reported elevated mental stability, myoclonus, and non-convulsive seizure epilepticus. Patients may be at risk for CIN if they have a serum cefepime trough concentration of > 20 mg/L. In 97. 5% by dose reduction or haltepime, with median time to increase of 3 days. Candidates for cefepime should be carefully selected In the current situation, where there are no CIN diagnostic tools and no drug monitoring system is widely available, candidates for cefepime should be carefully selected.

Source link: https://europepmc.org/article/MED/35971666

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions